Clinical Trials

643 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02362594 2026-03-05

MK-3475-054

1,019 enrolled 16 charts 1 FDA

Melanoma

NCT04222972 2026-03-05

AcceleRET-Lung

Phase 3 Terminated

223 enrolled 18 charts

Head & NeckThoracic

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT03976323 2026-02-25

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

1,003 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma

NCT03976362 2026-02-25

KEYLYNK-008

Phase 2 Active not recruiting

851 enrolled 25 charts

Tumor-Agnostic

Carcinoma

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

40 enrolled 67 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02811861 2026-02-23

CLEAR

1,069 enrolled 12 charts 1 FDA

Carcinoma, Renal Cell

NCT04221945 2026-02-20

KEYNOTE-A18

1,060 enrolled 30 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT04738487 2026-02-20

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

1,264 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05005442 2026-02-19

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

Other hematologic neoplasm

192 enrolled 22 charts

Hematologic Neoplasms

NCT05775289 2026-02-11

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

182 enrolled 35 charts

Carcinoma, Non-Small-Cell Lung

NCT03820986 2026-02-09

LEAP-003

674 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT03713593 2026-02-05

LEAP-002

794 enrolled 30 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT03829319 2026-02-05

LEAP-006

761 enrolled 31 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03898180 2026-02-05

LEAP-011

505 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT04776148 2026-02-05

MK-7902-017

563 enrolled 32 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT05226598 2026-02-05

MK-7684A-007

739 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT03040999 2026-02-04

KEYNOTE-412

804 enrolled 20 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

617 enrolled 29 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT02853331 2026-02-02

KEYNOTE-426

861 enrolled 24 charts 1 FDA

Carcinoma, Renal Cell

NCT03390504 2026-02-02

THOR

629 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT03884101 2026-02-02

LEAP-001

842 enrolled 25 charts

Endometrial Neoplasms

NCT05814666 2026-01-30

PEMDA-HN

69 enrolled 21 charts

Squamous Cell Carcinoma of Head and Neck

NCT04157517 2026-01-29

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

45 enrolled 44 charts

Melanoma, Neoplasms

NCT04260529 2026-01-29

CICILIA

BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

60 enrolled 18 charts

Tumor-Agnostic

Neoplasms

NCT05070247 2026-01-22

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

61 enrolled 29 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT04601857 2025-12-31

Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

43 enrolled 15 charts

Advanced and Metastatic Urothelial Cancer

NCT05141357 2025-12-24

HBI-8000

5 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT05179603 2025-12-24

A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]

14 enrolled 15 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04889118 2025-12-23

LEAP-003

131 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT03310957 2025-12-12

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

185 enrolled 23 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02362035 2025-12-11

KEYNOTE145

LymphoidOther hematologic neoplasmPlasma cell

161 enrolled 29 charts

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03924869 2025-12-11

KEYNOTE-867

Phase 3 Terminated

448 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04381650 2025-12-10

A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

161 enrolled 44 charts

Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT04428151 2025-12-04

LEAP-009

408 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT03358472 2025-12-03

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

89 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04704219 2025-12-03

KEYNOTE-B61

160 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT05383170 2025-11-28

Catalyst

6 enrolled 11 charts

Tumor-Agnostic

Neoplasms

NCT04570332 2025-11-26

SPOTLIGHT203

42 enrolled 12 charts

Melanoma

NCT04854499 2025-11-19

ELEVATE HNSCC

193 enrolled 27 charts

Squamous Cell Carcinoma of Head and Neck

NCT05256381 2025-11-17

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

GastrointestinalGynecologicThoracic

166 enrolled 43 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Ovarian Neoplasms, Colorectal Neoplasms

NCT06212752 2025-11-12

MK-3475A-D77

39 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

7 enrolled 10 charts